Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

Pubmed ID :30211081
Publication Date : //

A cancer vaccine with dendritic cells differentiated with GM-CSF and IFNα and pulsed with a squaric acid treated cell lysate improves T cell priming and tumor growth control in a mouse model.


Ovarian cancer is one of the most lethal gynecologic cancers. Relapses after remission are common, hence novel strategies are urgently needed. Our group has previously developed a vaccination approach based on dendritic cells pulsed with HOCl-oxidized tumor lysates. Here we investigate the improvement of this vaccine strategy using squaric acid treatment of cancer cells during tumor lysate preparation and by differentiating dendritic cells in the presence of GM-CSF and IFNα. Induction of cell death by squaric acid treatment was assessed with propidium iodide (PI) and Annexin V in ID8 tumor cells. High mobility group box 1 (HMGB1) immunogenic status was analyzed using a western blot-based method, as previously described. For immunological tests, ID8 cells expressing ovalbumin (ova-ID8) were treated with squaric acid before cell lysis. DCs prepared with the canonical GM-CSF and IL-4 differentiation cocktail or IFNα and GM-CSF were pulsed with tumor cell lysates and further matured in the presence of IFNγ and LPS (4-DCs and α-DCs respectively). DCs were then used in co-culture assays with ova-specific T cells and IFNγ and IL-4 secretion measured by ELISA. DC phenotypes were characterized by FACS. Finally, DCs were tested in an ovarian cancer mouse model measuring body weight and animal survival. Squaric acid treatment of mouse ovarian cancer cells induced tumor cell death as well as preserve HMGB1, a crucial Damage-associated molecular pattern (DAMP) signal, in its active reduced form. Squaric acid treatment of ID8-ova cells increased IFNγ and decreased IL-4 production from ova-specific T cells in co-culture experiments, promoting a more immunogenic cytokine secretion pattern. DCs differentiated in the presence of IFNα induced a considerable decrease in IL-4 production compared to canonical 4-DCs, without affecting IFNγ release. DC phenotyping demonstrated a more mature and immunogenic phenotype for IFNα-differentiated DCs. Vaccination in tumor-bearing mice showed that IFNα-differentiated DCs pulsed with squaric acid-treated lysates were the most potent at delaying tumor growth, improving animal survival. We identified squaric acid as a novel immunogenic treatment of tumor cells for cancer vaccines particularly efficient in prolonging animal survival when used in combination with IFNα-differentiated DCs. These promising results support future efforts for the clinical translation of this approach.

Authors : Mookerjee Ananda , Graciotti Michele , Kandalaft Lana ,

Related products :

Catalog number Product name Quantity
30-711 In vitro study revealed that RSRC2 might play a role in cell proliferation. RSRC2 may be a novel tumor suppressor of esophageal cancer cell growth. 0.1 mg
9-46029 Human Cancer PrimaCell™6: Colorectal Tumor Cells, primary cell culture 5 x 100 ml
9-47042 Human Cancer PrimaCell™18: Uterine Tumor Cells, primary cell culture set
9-46032 Human Cancer PrimaCell™9: Kidney Tumor Cells, primary cell culture 5 x 100 ml
9-47039 Human Cancer PrimaCell™16: Stomach Tumor Cells, primary cell culture set
9-46034 Human Cancer PrimaCell™11: Lung Tumor Cells, primary cell culture 5 x 100 ml
9-46035 Human Cancer PrimaCell™12: Ovarian Tumor Cells, primary cell culture 5 x 100 ml
9-46036 Human Cancer PrimaCell™13: Pancreatic Tumor Cells, primary cell culture 5 x 100 ml
9-46037 Human Cancer PrimaCell™14: Rectal Tumor Cells, primary cell culture 5 x 100 ml
9-47037 Human Cancer PrimaCell™14: Rectal Tumor Cells, primary cell culture set
9-47036 Human Cancer PrimaCell™13: Pancreatic Tumor Cells, primary cell culture set
9-46028 Human Cancer PrimaCell™5: Cervical Tumor Cells, primary cell culture 5 x 100 ml
9-46027 Human Cancer PrimaCell™4: Breast Tumor Cells, primary cell culture 5 x 100 ml
9-46026 Human Cancer PrimaCell™3: Bladder Tumor Cells, primary cell culture 5 x 100 ml
2-96033 Human Cancer PrimaCell™10: Liver Tumor Cells, primary cell culture Kit
2-96034 Human Cancer PrimaCell™11: Lung Tumor Cells, primary cell culture Kit
2-96035 Human Cancer PrimaCell™12: Ovarian Tumor Cells, primary cell culture Kit
2-96036 Human Cancer PrimaCell™13: Pancreatic Tumor Cells, primary cell culture Kit
2-96037 Human Cancer PrimaCell™14: Rectal Tumor Cells, primary cell culture Kit
2-96039 Human Cancer PrimaCell™16: Stomach Tumor Cells, primary cell culture Kit
2-96042 Human Cancer PrimaCell™18: Uterine Tumor Cells, primary cell culture Kit
9-46033 Human Cancer PrimaCell™10: Liver Tumor Cells, primary cell culture 5 x 100 ml
4-28037 Human Cancer PrimaCell™14: Rectal Tumor Cells, primary cell culture Kit
9-46024 Human Cancer PrimaCell™1: Esophageal Tumor Cells, primary cell culture 5 x 100 ml
9-46039 Human Cancer PrimaCell™16: Stomach Tumor Cells, primary cell culture 5 x 100 ml


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur | Gentaur





GENTAUR Ltd.
Unicorn House, Station Cl
Hertfordshire, Potters Bar EN6 1TL
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017
RIB 30004 00187 00010092253 10
BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG
IBAN FR76 3000 4001 8700 0100 9225 310
france@gentaur.com | Gentaur | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: +49 0241 40 08 90 86, +49 0241 95 78 94 78, +49 0241 40 08 90 86
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur | Gentaur